Agomelatine: an agent against anhedonia and abulia?

J Neural Transm (Vienna). 2015 Aug:122 Suppl 1:S3-7. doi: 10.1007/s00702-013-1126-6. Epub 2013 Dec 6.


Anhedonia and abulia are syndromes often presented as components of various psychiatric and neurological disorders, including depression, schizophrenia, stroke, multiple sclerosis and brain injury. On the basis of the hypothesis that alterations in the dopaminergic motivational system might be involved in the etiopathogenesis of these clinical phenomena, the antidepressant agomelatine is a highly interesting candidate substance for their treatment because of its indirect dopaminergic effects resulting from its melatoninergic and partial anti-serotoninergic properties. Systematic clinical studies are urgently needed to test the hypothesis that agomelatine might be a clinically useful and versatile anti-anhedonic and/or anti-abulic substance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acetamides / therapeutic use*
  • Anhedonia / drug effects*
  • Humans
  • Hypnotics and Sedatives / therapeutic use*
  • Mood Disorders / drug therapy*


  • Acetamides
  • Hypnotics and Sedatives
  • agomelatine